Cephalon submits OraVescent NDA
This article was originally published in Pharmaceutical Approvals Monthly
Cephalon submits an NDA for its effervescent buccal fentanyl product OraVescent. Announced Sept. 6, the application seeks an indication for management of breakthrough pain in patients with cancer who are already receiving or who are tolerant to opioid therapy for underlying persistent pain. "This NDA, submitted on schedule, is the fourth of five new product opportunities that Cephalon is pursuing over a 15-month period," the firm said. Cephalon previously indicated that its goal of achieving four NDA approvals in 2005-2006 could double the firm's size by 2008 (1Pharmaceutical Approvals Monthly May 2005, p. 13). The OraVescent NDA includes one pivotal trial with statistically significant pain improvements and interim analyses from three ongoing Phase III trials in opioid-tolerant patients...
You may also be interested in...
Cephalon goal of four NDA submissions in 14 months is on-track, with approvals forecast to double size of company by 2008. Pediatric sales force of 250 to be hired to detail modafinil for ADHD, with debut slated for early 2006. FDA rejects trade name Attenace. OraVescent breakthrough cancer pain NDA slated for Q3 2005; Gabitril sNDA for generalized anxiety in Q1 2006
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.